Business Description
Crescita Therapeutics Inc
NAICS : 325412
SIC : 3741
ISIN : CA2258471028
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 7.48 | |||||
Equity-to-Asset | 0.77 | |||||
Debt-to-Equity | 0.07 | |||||
Debt-to-EBITDA | 4.18 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | -0.36 | |||||
Beneish M-Score | -3.96 | |||||
WACC vs ROIC |
Growth Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 5.1 | |||||
3-Year EBITDA Growth Rate | -69.7 | |||||
3-Year FCF Growth Rate | -28.7 | |||||
3-Year Book Growth Rate | -2.7 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 76 | |||||
9-Day RSI | 60.02 | |||||
14-Day RSI | 55.09 | |||||
6-1 Month Momentum % | 2.44 | |||||
12-1 Month Momentum % | -35.38 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.8 | |||||
Quick Ratio | 2.54 | |||||
Cash Ratio | 1.93 | |||||
Days Inventory | 290.04 | |||||
Days Sales Outstanding | 66.43 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 1.1 | |||||
Shareholder Yield % | 6.58 |
Profitability Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 59.15 | |||||
Operating Margin % | -11.16 | |||||
Net Margin % | -11.33 | |||||
FCF Margin % | 11.85 | |||||
ROE % | -9.88 | |||||
ROA % | -7.48 | |||||
ROIC % | -20.05 | |||||
ROC (Joel Greenblatt) % | -22.84 | |||||
ROCE % | -6.81 | |||||
Years of Profitability over Past 10-Year | 4 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Price-to-Owner-Earnings | 6.3 | |||||
PS Ratio | 0.5 | |||||
PB Ratio | 0.46 | |||||
Price-to-Tangible-Book | 0.52 | |||||
Price-to-Free-Cash-Flow | 4.26 | |||||
Price-to-Operating-Cash-Flow | 4.26 | |||||
EV-to-EBIT | -0.26 | |||||
EV-to-EBITDA | 1.23 | |||||
EV-to-Revenue | 0.02 | |||||
EV-to-FCF | 0.18 | |||||
Price-to-Projected-FCF | 0.35 | |||||
Price-to-Net-Current-Asset-Value | 0.68 | |||||
Price-to-Net-Cash | 2.42 | |||||
Earnings Yield (Greenblatt) % | -384.62 | |||||
FCF Yield % | 24.42 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Crescita Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil C$) | 17.522 | ||
EPS (TTM) (C$) | -0.09 | ||
Beta | 0.63 | ||
Volatility % | 50.16 | ||
14-Day RSI | 55.09 | ||
14-Day ATR (C$) | 0.005688 | ||
20-Day SMA (C$) | 0.43075 | ||
12-1 Month Momentum % | -35.38 | ||
52-Week Range (C$) | 0.36 - 0.73 | ||
Shares Outstanding (Mil) | 19.54 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Crescita Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Crescita Therapeutics Inc Stock Events
Event | Date | Price(C$) | ||
---|---|---|---|---|
No Event Data |
Crescita Therapeutics Inc Frequently Asked Questions
What is Crescita Therapeutics Inc(TSX:CTX)'s stock price today?
When is next earnings date of Crescita Therapeutics Inc(TSX:CTX)?
Does Crescita Therapeutics Inc(TSX:CTX) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |